A risk/reward of approximately 4.6-to-1 and 32% upside to analyst consensus reflects high commercial expectations for a single cardiac product, offset by deeply negative free cash flow running at more than three times revenue, 18% short interest, and business quality below the minimum acceptable threshold.
Thesis pillars
- Large Analyst Consensus Upside→Stable
- Deep Cash Burn Survival Risk→Stable
- Single Product Revenue Concentration↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Cytokinetics, Incorporated (CYTK) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $62.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Below long-term trend.
Cytokinetics is a biopharmaceutical company that discovered and developed MYQORZO (aficamten), a cardiac myosin inhibitor FDA-approved in December 2025 for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Commercial sales in the United States began in Q1 2026, with... Read more
Sell if holding. Engine safety override at $62.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Below long-term trend. Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: speculative.
About Cytokinetics, Incorporated
About Cytokinetics, Incorporated
MYQORZO (aficamten), Cytokinetics' cardiac myosin inhibitor for symptomatic oHCM, received FDA approval in December 2025, European Commission approval in February 2026, and China NMPA approval in December 2025 — making it the company's first and only commercial product. U.S. commercial sales launched around January 27, 2026, with Germany commercialization targeted for Q2 2026 to be followed by other major European countries; Sanofi holds commercialization rights in China under a license agreement, and Bayer holds Japan rights under a separate collaboration and license agreement.
Cytokinetics targets a concentrated specialist prescriber base — approximately 10,000 cardiologists in the United States diagnose and initiate treatment for HCM, spanning academic centers of excellence and community cardiology settings. Revenue from MYQORZO comes from prescription sales subject to reimbursement negotiations with Medicare, Medicaid, commercial insurers, VA, DoD, and TriCare. The company has no manufacturing facilities and relies on single-source contract manufacturers for MYQORZO's active pharmaceutical ingredient, finished drug product, and European blister packaging; switching CMOs would require FDA or foreign regulatory re-approval, making the dependency difficult to reduce on short notice. Under a revenue interest agreement, RPI ICAV is entitled to 4.5% of worldwide annual net sales of MYQORZO and any future aficamten-containing products up to $5.0 billion. In September 2025, the United States administration announced plans to impose up to 100% tariffs on imported branded pharmaceutical products, creating potential cost uncertainty for the company's CMO-sourced API and finished goods.
Show full overview
The single largest near-term catalyst is ACACIA-HCM, a Phase 3 trial of aficamten in patients with non-obstructive HCM (nHCM), with top-line data expected in Q2 2026. A positive readout supporting a supplemental NDA would expand the addressable patient population beyond the oHCM-only label. Separately, in January 2026, Cytokinetics submitted a supplemental NDA to include MAPLE-HCM data in the MYQORZO label, with a potential approval expected in Q4 2026 pending standard review. GALACTIC-HF previously resulted in a complete response letter for omecamtiv mecarbil despite meeting its primary endpoint — illustrating that a positive Phase 3 readout does not guarantee regulatory approval.
See also: Healthcare · Biotechnology
From Cytokinetics, Incorporated's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Cytokinetics, Incorporated
Latest news
- NEWS Cytokinetics Announces Participation in Upcoming November Investor Conferences — fiscal.ai Nov 3, 2026 neutral
- NEWS Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions — fiscal.ai Nov 2, 2026 neutral
- NEWS Cytokinetics Announces Three Aficamten Presentations, Including Two Late-Breaking Orals In Non-Obstructive Hypertrophic — benzinga Nov 2, 2026 positive
- NEWS Cytokinetics Receives 'Zero to Launch' Award from IntegriChain — fiscal.ai Oct 22, 2026 positive
- NEWS Cytokinetics Schedules Third Quarter 2026 Financial Results Announcement — fiscal.ai Oct 21, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-04T11:54:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMYQORZO10-K Item 1: 'Our first commercial product is MYQORZO™ (aficamten)...which the FDA approved in December 2025'
- HIGHSuppliersingle source CMOs10-K Item 1A: 'We currently rely on single source CMOs for the manufacture of any or all of MYQORZO as a finished drug product and the active pharmaceutical ingredient'
- HIGHpipelineACACIA-HCM10-K Item 1: 'Aficamten continues to be evaluated in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with nHCM'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $62.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Below long-term trend. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $58.39. Score 5.4/10, moderate confidence.
Analyst target: $96.65 (+55.1% upside). Prior stop was $58.39. Stop-loss: $58.39.
Concentration risk — Product: MYQORZO; Concentration risk — Supplier: single source CMOs; Quality below floor (1.8 < 4.0).
Cytokinetics, Incorporated trades at a P/E of N/A (forward -14.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
28 analysts rate CYTK, with a consensus score of 4.1/5. 18 analysts publish price targets averaging $107.
What does Cytokinetics, Incorporated do?Cytokinetics is a biopharmaceutical company that discovered and developed MYQORZO (aficamten), a cardiac myosin...
Cytokinetics is a biopharmaceutical company that discovered and developed MYQORZO (aficamten), a cardiac myosin inhibitor FDA-approved in December 2025 for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Commercial sales in the United States began in Q1 2026, with Sanofi holding commercialization rights in China and Bayer in Japan; the company relies entirely on single-source contract manufacturers for all MYQORZO production.